Breaking News Instant updates and real-time market news.

JPM

JPMorgan

$106.95

0.15 (0.14%)

, WFC

Wells Fargo

$54.80

-1.22 (-2.18%)

12:17
07/13/18
07/13
12:17
07/13/18
12:17

Fly Intel: Wall Street's top stories at midday

Stocks on Wall Street were higher at midday as the S&P 500 rose above 2,800 for the first time since the middle of March. The Dow has also been strong, though not much of that outperformance is due to JPMorgan (JPM) after the bank and several of its large peers kicked off earnings season with their reports this morning. ECONOMIC EVENTS: In the U.S., the June trade price report was mixed, with a weaker than expected 0.4% import price decline and a stronger than expected 0.3% increase in export prices. The University of Michigan consumer sentiment survey was weaker than expected, falling 1.1 points to a 6-month low of 97.1 in the preliminary print for July. In Asia, China's exports were strong in June, rising 11.3%, while imports fell a bit short of expectations with an increase of 14.1%. COMPANY NEWS: Shares of JPMorgan advanced fractionally after it started off this summer's earnings season by reporting better than expected earnings for the second quarter. Of note, the bank's CEO Jamie Dimon said he sees "good global economic growth, particularly in the U.S." Meanwhile, Wells Fargo (WFC) slipped 2% after reporting downbeat results for Q2, with the company noting in presentation slides that the third party review of customer accounts is "ongoing." Citi (C) shares also fell about 2% after its quarterly report, though the bank's headline earnings for the quarter beat analysts' estimates. In addition, PNC Financial (PNC) reported better than expected results for the quarter and guided for third quarter net interest income to be up low-single digits... Meanwhile, AT&T (T) was in focus after the U.S. Department of Justice said it plans to appeal the approval of the merger between AT&T and Time Warner. In an interview on CNBC this morning, AT&T CEO Randall Stephenson said that he doesn't know exactly what the government basis will be for an appeal and that the move by the DOJ "changes nothing"... Additionally, Johnson & Johnson (JNJ) dipped about 1% after a Missouri jury awarded $4.69B to 22 women who alleged that use of J&J's talcum powder products caused their ovarian cancer. The jury award includes $550M in compensatory damages and $4.14B in punitive damages against the company. J&J responded by saying it "intends to pursue all available appellate remedies." MAJOR MOVERS: Among the noteworthy gainers was Biocept (BIOC), which surged 58% after it announced a provider agreement with Alliance Global FZ. Also higher was Achillion (ACHN), which gained 13% after it said it began dosing in its Phase 1 trial of ACH-5548. Among the notable losers was Gogo (GOGO), which fell 11%, reversing last night's afterhours gains following the company's announcement of a strategic review. Also lower was Ingredion (INGR), which dropped 11% after it announced a $125M cost savings program, provided lower than expected Q2 guidance, and cut its outlook for fiscal 2018. INDEXES: Near midday, the Dow was up 93.18, or 0.37%, to 25,018.07, the Nasdaq was up 13.35, or 0.17%, to 7,837.26, and the S&P 500 was up 4.74, or 0.17%, to 2,803.03.

JPM

JPMorgan

$106.95

0.15 (0.14%)

WFC

Wells Fargo

$54.80

-1.22 (-2.18%)

C

Citi

$66.98

-1.56 (-2.28%)

PNC

PNC Financial

$139.10

1.1 (0.80%)

T

AT&T

$31.55

-0.675 (-2.10%)

JNJ

Johnson & Johnson

$126.01

-1.76 (-1.38%)

BIOC

Biocept

$10.32

3.83 (59.01%)

ACHN

Achillion

$3.29

0.36 (12.29%)

GOGO

Gogo

$4.24

-0.6 (-12.40%)

INGR

Ingredion

$98.60

-12.13 (-10.95%)

  • 13

    Jul

  • 13

    Jul

  • 13

    Jul

  • 13

    Jul

  • 13

    Jul

  • 17

    Jul

  • 24

    Jul

  • 26

    Jul

  • 02

    Aug

  • 08

    Aug

  • 12

    Oct

  • 12

    Oct

  • 12

    Oct

  • 14

    Jan

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 13

    Jul

  • 12

    Oct

JPM JPMorgan
$106.95

0.15 (0.14%)

07/09/18
GSCO
07/09/18
NO CHANGE
GSCO
Bank of America, Morgan Stanley top ideas into Q2 earnings season, says Goldman Sachs
Goldman Sachs analyst Richard Ramsden expects Bank of America (BAC) and Morgan Stanley (MS) to beat consensus estimates in Q2. The analyst argues that both appear best positioned, while he sees risk for U.S. Bancorp (USB) and JPMorgan (JPM). Ramsden highlights Bank of America given the material valuation dislocation that looks to support the stock over time. Additionally, the analyst expects an expense and NII beat for Morgan Stanley.
06/08/18
BERN
06/08/18
NO CHANGE
BERN
Bernstein offers list of possible CEOs for Amazon-Berkshire-JPMorgan venture
After Berkshire' (BRK.A) Warren Buffett and JPMorgan's (JPM) Jamie Dimon announced on CNBC that they have selected a CEO for their healthcare joint venture with Amazon (AMZN) and added that they would announce the name in about two weeks, Bernstein analyst Lance Wilkes noted that Geisinger CEO David Feinberg denied accepting the position and said he is committed to Geisinger. The ultimate choice of the CEO will inform on the intended scope of the NewCo and how the companies will prioritize strategic direction and needed capabilities, said Wilkes, who offered a list of potential CEO candidates that includes Gary Loveman, Rick Jelinek, Matt Manders, Patrick Conway, Amir Rubin, Owen Tripp, Chris Grant, Marc Harrison, Andy Slavitt, Todd Park and Peter Orszag.
06/21/18
BERN
06/21/18
NO CHANGE
BERN
Amazon/JPMorgan/Berkshire venture still negative for drug supply chain, says Bernstein
Bernstein analyst Lance Wilkes notes that Amazon (AMZN), Berkshire Hathaway (BRK.A; BRK.B) and JPMorgan (JPM) announced the appointment of Atul Gawande as the CEO of their new healthcare joint venture, effective July 9th. The analyst sees this appointment as indicating an emphasis on enablement of change in the system, along with thought and policy leadership, and believes the appointment of an operating oriented President or COO could refine the outlook for scope. Wilkes continues to see this venture as negative for drug supply chain and self-insured employer oriented MCOs.
06/29/18
DBAB
06/29/18
NO CHANGE
DBAB
Deutsche declares Wells Fargo, SunTrust, Huntington the CCAR winners
Deutsche Bank analyst Matt O'Connor views Wells Fargo (WFC), SunTrust (STI) and Huntington Bancshares (HBAN) as the winners of the Federal Reserve's Comprehensive Capital Analysis and Review. The banks separately disclosed planned dividend increases and buybacks for the next four quarters, O'Connor tells investors in a research note. He points out that while JPMorgan (JPM), KeyCorp (KEY) and M&T Bank (MTB) "all used the mulligan," he does not view this as negative.
WFC Wells Fargo
$54.80

-1.22 (-2.18%)

07/02/18
MSCO
07/02/18
UPGRADE
MSCO
Equal Weight
Wells Fargo upgraded to Equal Weight from Underweight at Morgan Stanley
06/29/18
06/29/18
NO CHANGE

Goldman says Wells Fargo, Huntington, Regions among biggest winners of CCAR
Goldman Sachs analyst Richard Ramsden said the Fed's CCAR results came in largely better than expected, calling Wells Fargo (WFC), Huntington Bancshares (HBAN), Regions Financial (RF), SunTrust (STI) and Fifth Third (FITB) the biggest relative winners in his view. He believes the market will be focused on banks' 25% dividend growth announcements and believes the CCAR results can be a catalyst for a relief rally.
07/02/18
07/02/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. RPM (RPM) upgraded to Neutral from Underweight at JPMorgan with analyst Jeffrey Zekauskas saying he believes investors are now more willing to pay a higher multiple for RPM EBITDA because of new possibilities of cost reduction, changes in capital structure, or overall changes to the company given the involvement of activist Elliott Management. 2. Capital One (COF) upgraded to Outperform from Neutral at Credit Suisse with analyst Moshe Orenbuch citing improving credit quality, ahead of the industry. 3. Wells Fargo (WFC) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Betsy Graseck stating that the bank's passing the 2018 CCAR stress test removes an overhang and indicates to her that the Fed is receptive of the changes Wells is making. 4. ZTE Corp. (ZTCOY) upgraded to Buy from Underperform at Jefferies with analyst Edison Lee saying Li Zixue becoming Chairman of the Board is an important step toward meeting the conditions of the company's settlement with the U.S. 5. Curtiss-Wright (CW) upgraded to Outperform from Market Perform at William Blair with analyst Nicholas Heymann saying the valuation is "compelling" following the recent correction in the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/02/18
07/02/18
UPGRADE
Target $62

Equal Weight
Wells Fargo upgraded to Equal Weight after CCAR test pass at Morgan Stanley
As previously reported, Morgan Stanley analyst Betsy Graseck upgraded Wells Fargo to Equal Weight from Underweight, stating that the bank's passing the 2018 CCAR stress test removes an overhang and indicates to her that the Fed is receptive of the changes Wells is making. Not only did Wells pass, the Fed approved buybacks that were almost twice her estimates, Graseck tells investors. Higher buybacks took her EPS estimate up 4% and Graseck raised her price target on Wells Fargo shares to $62 from $57.
C Citi
$66.98

-1.56 (-2.28%)

05/17/18
DAIW
05/17/18
DOWNGRADE
DAIW
Buy
Citi downgraded to Buy from Strong Buy at Daiwa
06/20/18
DBAB
06/20/18
UPGRADE
Target $76
DBAB
Buy
Citi upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Matt O'Connor upgraded Citi (C) to Buy and raised his price target for the shares to $76 from $74. The analyst also calls Goldman Sachs (GS) and Wells Fargo (WFC) his top picks ahead of the Q2 reporting season.
06/20/18
06/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Citi (C) upgraded to Buy from Hold at Deutsche Bank. 2. BT Group (BT) upgraded to Buy from Hold at Jefferies with analyst Jeremy Dellis saying reducing the dividend to increase investment in fiber-to-the-premises networks to satisfy demands by British telecommunications regulator Ofcom could make BT a "geat deal more investable." 3. Duke Energy (DUK) upgraded to Buy from Neutral at BofA/Merrill with analyst Julien Dumoulin-Smith citing recent share underperformance and resolved regulatory overhangs. 4. Glatfelter (GLT) upgraded to Buy from Neutral at DA Davidson with analyst Steven Chercover saying he is "incrementally positive" on the stock based on his view of the announced acquisition of GP's European airlaid nonwoven business, which adds 35K tonnes per year in capacity to the company's existing 129K tpy. 5. Intelsat (I) upgraded to Outperform from Sector Perform at RBC Capital with analyst Wilton Fry citing his expected FCC release of the Notice of Proposed Rulemaking this week that will lead to adoption of the company's C-band proposal, "conservatively" estimating that this could add over $19 in earnings per share. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/18
OPCO
06/29/18
NO CHANGE
Target $88
OPCO
Outperform
Oppenheimer says 'particularly pleased' with Citi's $17.6B share buyback
Following the release of CCAR results for 2018, Oppenheimer analysts Chris Kotowski and Ben Chittenden told investors in a research note that they are "particularly pleased" with Citi's (C) $17.6B share buyback, up 13% from last year and above their $16.5B estimate, while the dividend increase to 45c was also 5c better than expected. The analysts noted that both Goldman (GS) and Morgan Stanley (MS) got "conditional passes" on their capital plans, as both banks "ran a bit afoul" of the supplementary leverage ratio limitation.
PNC PNC Financial
$139.10

1.1 (0.80%)

01/16/18
RBCM
01/16/18
NO CHANGE
Target $170
RBCM
Top Pick
PNC Financial price target raised to $170 from $145 at RBC Capital
RBC Capital analyst Gerard Cassidy raised his price target to $170 after the bank's above-consensus Q4 earnings driven by "stronger noninterest income and a lower loan loss provision". The analyst also noted a 0.9% increase in PNC's average loan and the expected positive impact from lower U.S. corporate tax rates. Cassidy keeps his Top Pick rating on PNC, forecasting continued strong results in 2018-2019, assuming 2-3 interest rate increases in each year.
04/16/18
BARD
04/16/18
NO CHANGE
Target $153
BARD
Outperform
PNC Financial weakness overdone, says Baird
Baird analyst David George said PNC Financial posted a clean quarter and he would be a buyer of the shares on the post-earnings weakness. The analyst noted fees were down seasonally, but the bank posted good year-over-year growth. George maintained his Outperform rating and $153 price target on PNC Financial shares.
05/30/18
BARD
05/30/18
NO CHANGE
Target $153
BARD
Outperform
PNC Financial added as Fresh Pick at Baird
Baird analyst David George said the weakness in PNC Financial is a buying opportunity and said it screens as one of the better values among regional banks. The analyst likes the bank's competitive positioning, solid intermediate-term outlook, and its current valuation. George reiterated his Outperform rating and $153 price target on PNC Financial shares.
06/14/18
RBCM
06/14/18
NO CHANGE
Target $170
RBCM
Top Pick
PNC Financial EPS view cut at RBC Capital on reduced mortgage banking outlook
RBC Capital analyst Gerard Cassidy lowered his PNC Financial FY18 EPS view to $10.51 from $10.60 and FY19 view to $11.32 from $11.46 after the recent commentary by the management that its Q2 mortgage banking revenues are tracking to be 12% lower than in Q1. The analyst keeps his Top Pick rating and $170 price target however, saying the bank is well positioned for higher interest rates that would expand its net interest income and also has a high 42% of the total component for its non-interest income. Cassidy adds that the regulatory environment benefits could also exceed his expectations.
T AT&T
$31.55

-0.675 (-2.10%)

07/13/18
07/13/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. VF CORP DOUBLE UPGRADE: BofA Merrill Lynch analyst Robert Ohmes upgraded VF Corp (VFC) to Buy from Underperform and raised his price objective to $96 from $65 ahead of the company's earnings report on July 20, telling investors in a research note that he believes Vans will be a "go-to-brand" for the back-to-school selling season. He said his channel checks indicate accelerating momentum in Vans, especially classic styles, and that the $50-$60 price point is attractive given consumers' shift to value. RAYMOND JAMES DOWNGRADES AT&T: Raymond James downgraded AT&T (T) to Market Perform from Outperform. Analyst Frank Louthan said he views the Department of Justice appeal of the Time Warner case as a negative and said it is a "frustrating delay." Louthan expects the suit to be a "significant overhang" for an extended period of time, which will limit share appreciation, but remains confident AT&T will prevail. AT&T is lower by 2% in late morning trading. STIFEL STARTS GALMED WITH A BUY: Stifel analyst Adam Walsh initiated Galmed (GLMD) with a Buy rating and $35 price target, calling it a "legitimate late-stage NASH play" after Aramchol recently proved itself in a Phase 2 trial as a clearly active and "very safe" compound for treating NASH. Galmed is trading higher by over 17% in late morning trading. MORGAN STANLEY HIKES WWE TARGET TO $100: Morgan Stanley analyst Benjamin Swinburne said that WWE (WWE), by securing rights fees in its new five-year agreements with NBC (CMCSA, CMCSK) and Fox (FOX, FOXA) that are 3.6 times higher than its prior five-year broadcast agreement with NBC, has gained a "massive increase" in earnings power and "extremely high" visibility into the associated revenue. Given the recently announced deals, he raised his price target on WWE shares to $100 from $58 and kept an Overweight rating on the stock. WILLIAM BLAIR CALLS KEMPER PULLBACK 'BUYING OPPORTUNITY': William Blair analyst Adam Klauber said he views shares of Kemper (KMPR) as "even more attractive" after the recent pullback, which he attributes to selling pressures from Infinity Property shareholders receiving Kemper stock. Klauber said Kemper "continues to be our top conviction idea," and kept an Outpeform rating on the name. Kemper is higher by 4.8% in late morning trading.
07/13/18
JEFF
07/13/18
NO CHANGE
Target $35
JEFF
Hold
DOJ faces 'uphill battle' in AT&T appeal, says Jefferies
While the Department of Justice's appeal of the AT&T-Time Warner case creates some uncertainty, the agency "faces an uphill battle," Jefferies analyst John Janedis tells investors in a research note. The analyst notes that Judge Leon was very clear in his ruling that he believed the government did not meet its burden of proof in the case, and discouraged the DOJ from asking for a stay. Janedis believes it could take a year or more before a final decision is made. He keeps a Hold rating on AT&T with a $35 price target.
07/13/18
07/13/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AT&T (T) downgraded to Market Perform from Outperform at Raymond James with analyst Frank Louthan saying he views the Department of Justice appeal of the Time Warner case as a negative and said it is a "frustrating delay." Louthan expects the suit to be a "significant overhang" for an extended period of time, which will limit share appreciation, but remains confident AT&T will prevail. 2. Incyte (INCY) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Matthew Harrison saying he believes key catalysts are unlikely until 2019 and he expects the stock to trade with the market in the meantime. 3. WisdomTree (WETF) was downgraded to Market Perform from Outperform at Keefe Bruyette and to Neutral from Buy at Citi. 4. Cedar Fair (FUN) downgraded to Neutral from Outperform at Macquarie. 5. Ingredion (INGR) downgraded to Sell from Neutral at Citi with analyst David Driscoll saying he expects the stock's valuation multiples to compress as investors sort through the number of issues that have come to light. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/13/18
MSCO
07/13/18
NO CHANGE
Target $37
MSCO
Overweight
Market likely to place low odds on AT&T deal reversal, says Morgan Stanley
After the DOJ decided to appeal District Court Judge Leon's order approving AT&T's merger with Time Warner, Morgan Stanley analyst Simon Flannery said he believes the market is likely to heavily rely on Judge Leon's "strongly worded decision" and assign a fairly low probability on a possible reversal of the deal. Even if AT&T were forced to divest assets, it would be into a fairly healthy market, added Flannery, who keeps an Overweight rating and $37 price target on the stock.
JNJ Johnson & Johnson
$126.01

-1.76 (-1.38%)

07/13/18
FBCO
07/13/18
NO CHANGE
Target $151
FBCO
Outperform
J&J verdict likely to increase attention on lawsuits, says Credit Suisse
After a Missouri jury on Thursday ordered Johnson & Johnson to pay $4.69B to 22 women who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer, Credit Suisse analyst Vamil Divan said the large number of ongoing litigations are gaining the attention of investors and is not expected to slow. Given the number of cases related to both talc and mesh and the size of the potential verdicts, Divan says it is "challenging" to put reasonable ranges on what J&J's ultimate liability may end up being, though he notes that J&J has been able to overturn many of the cases and has appealed all of the unfavorable verdicts. Divan maintains an Outperform rating and $151 price target.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
07/12/18
GSCO
07/12/18
UPGRADE
GSCO
Neutral
Johnson & Johnson upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Jami Rubin upgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $134. The shares closed yesterday down $1.11 to $126.24. The stock is down 10% year-to-date and 15% from its recent all-time high of $148, Rubin tells investors in a research note. She notes J&J is trading in line with the large cap Pharmaceuticals group at 15 times 2019 estimates. The company's non-operational earnings revisions are now better understood by investors at current share levels, Rubin contends. The analyst this morning also downgraded Perrigo (PRGO) to Sell from Neutral.
07/12/18
07/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Neutral from Sell at Goldman Sachs with analyst Jami Rubin saying the stock is down 10% year-to-date and 15% from its recent all-time high of $148. 2. Hallmark Financial (HALL) upgraded to Outperform from Market Perform at Raymond James. 3. Transocean (RIG), Ensco (ESV), and Rowan Companies (RDC) were upgraded to Buy from Hold at Tudor Pickering. 4. Precision Drilling (PDS) and Nabors Industries (NBR) were upgraded to Overweight from Equal Weight at Morgan Stanley. 5. CA Technologies (CA) upgraded to Market Perform from Underperform at Wells Fargo and Bernstein. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BIOC Biocept
$10.32

3.83 (59.01%)

05/23/18
WEST
05/23/18
DOWNGRADE
WEST
Neutral
Biocept downgraded to Neutral from Outperform at WestPark Capital
WestPark Capital analyst Lauren Chung downgraded Biocept to Neutral citing "limited funds to the balance sheet" following the company's Q1 results. The analyst wants to see an inflection in sales growth, or a strategic partnership, before getting more constructive on the shares.
04/04/18
WEST
04/04/18
NO CHANGE
Target $1
WEST
Outperform
Biocept price target lowered to $1 from $3 at WestPark Capital
WestPark Capital analyst Lauren Chung lowered her price target for Biocept to $1 following the company's Q4 results but maintains an Outperform rating on the name. While sales growth is slower than expected, Biocept continues to make "meaningful progress as an emerging pure play liquid biopsy diagnostics company," Chung tells investors in a post-earnings research note. Further, she views the Thermo Fisher collaboration as promising.
10/04/17
WEST
10/04/17
NO CHANGE
WEST
Biocept marketing agreement a positive, says WestPark Capital
WestPark Capital analyst Lauren Chung said Biocept's new promotion and marketing agreement with Miraca Life Sciences to market Biocept's tests and services in the U.S. will let Biocept to more aggressively boost sales without incurring material cost to the company, and could expand Biocept's reach for tests country wide. Chung rates Biocept a Buy with a $3 price target.
ACHN Achillion
$3.29

0.36 (12.29%)

12/11/17
LEER
12/11/17
NO CHANGE
Target $5
LEER
Outperform
Achillion '4471 on its way toward meaningful remissions, says Leerink
After speaking with MEDACorp nephrologists and conducting an analysis of recent data on the first two patients with C3 glomerulopathy treated with Achillion's ACH-4471, Leerink analyst Joseph Schwartz has an "enhanced appreciation" of the early signal of decreased proteinuria and market opportunity for it in C3G. The analyst believes '4471 is converging on modified partial remissions, which the FDA has stated may be used as a primary endpoint in other orphan kidney diseases. Schwartz is looking forward to data updates in 2018 on higher doses, longer duration of therapy, and more patients. He reiterates an Outperform rating and $5 price target on the shares.
12/15/17
LEER
12/15/17
NO CHANGE
Target $5
LEER
Outperform
Achillion CMO departure not a sign of problems with pipeline, says Leerink
Leerink analyst Joseph Schwartz spoke with Achillion after news that CMO David Apelian delivered his resignation and the analyst believes his departure is not indicative of any problems with the company's pipeline programs. Schwartz, who continues to see current levels as an attractive entry point to buy shares ahead of more de-risking data next year in the C3G market, keeps an Outperform rating on Achillion.
02/08/18
RILY
02/08/18
INITIATION
Target $3.5
RILY
Neutral
Achillion initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Achillion Pharmaceuticals with a Neutral rating and $3.50 price target.
05/21/18
LEHM
05/21/18
UPGRADE
Target $5
LEHM
Equal Weight
Achillion upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Geoffrey Meacham upgraded Achillion Pharmaceuticals to Equal Weight with an unchanged price target of $5. The analyst sees minimal downside risk from current valuation levels.
GOGO Gogo
$4.24

-0.6 (-12.40%)

04/11/18
WBLR
04/11/18
NO CHANGE
WBLR
Google interest ups chances of in-flight Wi-Fi acquisition, says William Blair
"We have seen this movie before" is what William Blair analyst Louie DiPalma says after Bloomberg reported yesterday that Google (GOOG, GOOGL) is in advanced talks to acquire Nokia's in-flight connectivity hardware business. Google joins a long list of technology, telecom, and media providers that have exhibited a strategic interest in in-flight Wi-Fi, "although all have thus far stayed on the perimeter," DiPalma tells investors in a research note. The analyst notes that incumbents Gogo (GOGO), Panasonic (PCRFY), ViaSat (VSAT), Global Eagle Entertainment (ENT), and Inmarsat (IMASY) have invested billions toward satellite capacity and infrastructure. The industry is all about scale and potential new entrants would not have any, DiPalma contends. He believes it would take any new entrant many years to build a network from scratch, obtain regulatory approvals, and procure line-fit partnerships. The analyst thinks Google's interest in in-flight connectivity increases the probability that a tech or telecom company would buy an incumbent in the space. DiPalma has Outperform ratings on ViaSat and Gogo and a Market Perform rating on Global Eagle.
05/18/18
NORL
05/18/18
NO CHANGE
Target $1.5
NORL
Underperform
Gogo price target lowered to $1.50 from $3.50 at Northland
Norhtland analyst Paul Penney believes Gogo's issues remain "far reaching and deep," and as a result, cut estimates to take in account lower business and profitability levels. Penney said Gogo's excessive capex spending levels are not sustainable and expects continued equity erosion, leading the analyst to cut his price target to $1.50 from $3.50 and reiterate an Underperform rating.
05/21/18
UBSW
05/21/18
DOWNGRADE
Target $7
UBSW
Neutral
Gogo downgraded to Neutral from Buy at UBS
UBS downgraded Gogo to Neutral from Buy and lowered its price target to $7 from $14.
05/30/18
MSCO
05/30/18
NO CHANGE
Target $3
MSCO
Underweight
Gogo price target lowered to $3 from $7 at Morgan Stanley
Morgan Stanley analyst Simon Flannery said Gogo's recent weak results raise questions about its underlying business, financial model and ability to generate positive free cash flow. Given his expectations for significantly lower commercial aviation North America revenue and profitability, Flannery cut his 2018 adjusted EBITDA estimate for Gogo by about 55% and his 2019/2020 estimates by about 15%. He lowered his price target on Gogo shares to $3 from $7 and maintains an Underweight rating on the stock.
INGR Ingredion
$98.60

-12.13 (-10.95%)

07/13/18
SBSH
07/13/18
DOWNGRADE
SBSH
Sell
Ingredion downgraded to Sell from Neutral at Citi
07/13/18
07/13/18
DOWNGRADE
Target $95

Sell
Ingredion downgraded to Sell after guidance cut at Citi
As previously reported, Citi analyst David Driscoll downgraded Ingredion to Sell from Neutral after the company lowered its Q2 and 2018 EPS forecast, stating that he expects the stock's valuation multiples to compress as investors sort through the number of issues that have come to light. He set a $95 price target on Ingredion shares.
07/13/18
07/13/18
NO CHANGE
Target $145

Buy
Ingredion long-term thesis remains intact, says Jefferies
Jefferies analyst Akshay Jagdale says the long-term thesis on Ingredion remains intact despite the company's "disappointing" Q2 preannouncement. HFCS is a fairly small portion of Ingredion's overall portfolio and been in secular decline for some time, Jagdale tells investors in a research note. The analyst's long-term thesis is predicated more on Specialty business growth, which he says remains on track. Further, he believes the newly announced cost savings program should accelerate margin expansion. Jagdale reiterates a Buy rating on Ingredion with a $145 price target.

TODAY'S FREE FLY STORIES

TXT

Textron

$65.88

0.81 (1.24%)

11:06
10/15/18
10/15
11:06
10/15/18
11:06
Hot Stocks
TRU Simulation + Training, FlightSafety International enter LOI to form JV »

TRU Simulation +…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

11:05
10/15/18
10/15
11:05
10/15/18
11:05
Hot Stocks
Breaking Hot Stocks news story  »

Bio Rad Laboratories…

11:05
10/15/18
10/15
11:05
10/15/18
11:05
General news
Today's U.S. reports »

Today's U.S. reports…

MANU

Manchester United

$21.87

0.59 (2.77%)

11:03
10/15/18
10/15
11:03
10/15/18
11:03
Periodicals
Manchester United target for possible takeover by Saudi prince, The Sun says »

Saudi Crown Prince…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$75.53

-1.43 (-1.86%)

, EQIX

Equinix

$399.68

3.96 (1.00%)

11:03
10/15/18
10/15
11:03
10/15/18
11:03
Hot Stocks
NetApp appoints Debra McCowan as chief human resources officer »

NetApp (NTAP) announced…

NTAP

NetApp

$75.53

-1.43 (-1.86%)

EQIX

Equinix

$399.68

3.96 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 10

    Dec

SMH

Market Vectors Semiconductor

$96.42

-0.92 (-0.95%)

11:03
10/15/18
10/15
11:03
10/15/18
11:03
Technical Analysis
Technical Take: Market Vectors Semiconductor breaks support, nears 52-week lows »

The Market Vectors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMB

iShares JP Morgan USD Emerging Markets Bond ETF

$105.88

0.04 (0.04%)

11:00
10/15/18
10/15
11:00
10/15/18
11:00
Options
Position adjustment in Emerging Markets bond ETF »

Position adjustment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$5.25

0.11 (2.14%)

10:58
10/15/18
10/15
10:58
10/15/18
10:58
Hot Stocks
Viceroy: MiMedx's appointment of Alvarez, Marsal 'conflict of interest' »

In an open letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ATVI

Activision Blizzard

$74.92

-3.07 (-3.94%)

, MCD

McDonald's

$164.56

0.74 (0.45%)

10:57
10/15/18
10/15
10:57
10/15/18
10:57
Recommendations
Fly Intel: Today's top analyst calls on Wall Street »

Check out today's…

ATVI

Activision Blizzard

$74.92

-3.07 (-3.94%)

MCD

McDonald's

$164.56

0.74 (0.45%)

TPR

Tapestry

$42.89

-0.92 (-2.10%)

LULU

Lululemon

$143.24

-0.46 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 23

    Oct

  • 19

    Nov

10:55
10/15/18
10/15
10:55
10/15/18
10:55
Conference/Events
Wedbush restaurants analyst to hold a luncheon »

Restaurants Analyst…

WPC

W.P. Carey

$63.80

0.61 (0.97%)

, GPN

Global Payments

$115.68

-1.72 (-1.47%)

10:54
10/15/18
10/15
10:54
10/15/18
10:54
Conference/Events
Wedbush IT services & payments analyst to hold dinner meeting »

In conjunction with the…

WPC

W.P. Carey

$63.80

0.61 (0.97%)

GPN

Global Payments

$115.68

-1.72 (-1.47%)

FDC

First Data

$23.21

0.02 (0.09%)

TSS

TSYS

$92.71

-1.235 (-1.31%)

SQ

Square

$73.51

-0.455 (-0.62%)

PYPL

PayPal

$77.74

-1.28 (-1.62%)

MA

MasterCard

$200.90

-3.06 (-1.50%)

V

Visa

$138.45

-1.57 (-1.12%)

ADS

Alliance Data

$211.66

-2.09 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 13

    Nov

  • 26

    Nov

  • 03

    Mar

UNFI

United Natural Foods

$26.66

-0.48 (-1.77%)

, SVU

Supervalu

$32.47

-0.005 (-0.02%)

10:54
10/15/18
10/15
10:54
10/15/18
10:54
Recommendations
United Natural Foods, Supervalu analyst commentary  »

RBC says United Natural…

UNFI

United Natural Foods

$26.66

-0.48 (-1.77%)

SVU

Supervalu

$32.47

-0.005 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

NUGT

Direxion Gold Miners Bull

$16.72

1.32 (8.57%)

10:51
10/15/18
10/15
10:51
10/15/18
10:51
Technical Analysis
Technical Take: Direxion Gold Miners Bull has bullish price pattern »

There is an active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CL

Colgate-Palmolive

$62.80

0.26 (0.42%)

10:50
10/15/18
10/15
10:50
10/15/18
10:50
Options
Put sales in Colgate as implied volatility reaches 52-week highs »

Put sales in Colgate as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVU

Supervalu

$32.47

-0.005 (-0.02%)

, UNFI

United Natural Foods

$26.62

-0.52 (-1.92%)

10:49
10/15/18
10/15
10:49
10/15/18
10:49
Earnings
Supervalu reports Q2 EPS ($1.49), may not compare to consensus 37c »

Reports Q2 revenue…

SVU

Supervalu

$32.47

-0.005 (-0.02%)

UNFI

United Natural Foods

$26.62

-0.52 (-1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

10:45
10/15/18
10/15
10:45
10/15/18
10:45
General news
Breaking General news story  »

8-Week Bill Announcement…

10:45
10/15/18
10/15
10:45
10/15/18
10:45
General news
Breaking General news story  »

4-Week Bill Announcement…

AAPL

Apple

$219.33

-2.77 (-1.25%)

10:42
10/15/18
10/15
10:42
10/15/18
10:42
Periodicals
Kuo says 2019 iPhones to have same water resistance as iPhone XS, MacRumors says »

Apple analyst Ming-Chi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$31.54

0.63 (2.04%)

10:40
10/15/18
10/15
10:40
10/15/18
10:40
Options
American Airlines calls active with shares seeing relative strength »

American Airlines calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

10:40
10/15/18
10/15
10:40
10/15/18
10:40
General news
Treasury Action: Treasury introduces its new 8-week bill today »

Treasury Action: Treasury…

10:39
10/15/18
10/15
10:39
10/15/18
10:39
Conference/Events
RBC Capital restaurants/food analyst to hold analyst/industry conference call »

Consumer/Food &…

AZN

AstraZeneca

$37.30

0.15 (0.40%)

10:37
10/15/18
10/15
10:37
10/15/18
10:37
Periodicals
AstraZeneca suspends investments in Britain due to Brexit, Reuters reports »

AstraZeneca has halted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

  • 07

    Nov

BAC

Bank of America

$27.83

-0.595 (-2.09%)

10:35
10/15/18
10/15
10:35
10/15/18
10:35
Hot Stocks
Bank of America reports September card write-offs 2.59% vs. 2.75% last month »

Reports September 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 24

    Oct

EVA

Enviva

$30.82

0.32 (1.05%)

10:35
10/15/18
10/15
10:35
10/15/18
10:35
Hot Stocks
Enviva: Facilities incured 'limited' damage from Hurricane Michael »

Enviva Partners reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMNY

Helios and Matheson

$0.02

0.0001 (0.58%)

10:33
10/15/18
10/15
10:33
10/15/18
10:33
Hot Stocks
Helios and Matheson: Proxy firms recommend voting for reverse stock split »

Helios and Matheson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.